Credit: John Griffin, Stony Brook University
Dr. Iwao Ojima, center, developed a second generation taxane formulation that shows such promise to treat cancer that is has been licensed for product development. With Dr. Ojima are Sean Boykevisch, PhD, Director of Stony Brook’s Intellectual Property Partners, left, and James E. Egan, CEO of TargaGenix.